The global end stage renal disease drugs market is anticipated to grow at a significant CAGR during the forecast period. End stage kidney disease, also known as the late-stage renal disease, refers to a medical condition when chronic kidney disease reaches an advanced or its last stage. In this disease, the kidneys fail to work, as they otherwise function in order to meet the body’s needs. The market growth for their drugs is majorly attributed to the growing number of patients suffering from kidney failure, all over the globe. Factors that increase the risk of end stage renal disease include smoking, hypertension, diabetes, and the geriatric population. In fact, the most common factor includes diabetes, whereas hypertension (high blood pressure) is considered to be the second most frequent cause of this disease.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/end-stage-renal-disease-drugs-market
According to the National Kidney Foundation (NKD), approximately 10% of the global population suffers from chronic kidney diseases and millions die each year. As per the same source, the geriatric population suffers the condition most in emerging economies such as China and India. The number of patients continues to increase at a rate of 5-7% per year. Chronic kidney disease is estimated to be more common in women than men (15% vs 12%). Adding to this, the constantly growing number of patients suffering from hypertension and diabetes are also likely to fuel the end stage renal disease drugs market growth. As per the World Health Organization (WHO), in 2019, around 1.13 billion people globally had hypertension. Adding to this, from 2014-2016, hypertension and diabetes were responsible for nearly 75% of the global kidney failure cases.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Pfizer Inc., Novartis International AG, and Eli Lilly and Co., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global End Stage Renal Disease Drugs Market Report by Segment
By Type
- Calcium Succinate
- Mk-3866
- Sanguinate
- Pacritinib
- Others
By Application
- Hospitals
- Clinics
- Research Institutes
A full report of End Stage Renal Disease Drugs Market is available at: https://www.omrglobal.com/industry-reports/end-stage-renal-disease-drugs-market
End Stage Renal Disease Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Pfizer Inc.
- Novartis International AG
- Eli Lilly and Co.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
